NYR -Brain Injury Program GLP Studies Further Update 5

Nyrada Inc (ASX: NYR) have released an announcement updating the market on the Good Laboratory Practice (GLP) studies. The latest dog toxicology study provided continuing data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate NYR-BI03. This was an important study given dogs are a higher-order species than rats, having physiological systems closely resembling those of humans. This includes their ability to metabolise certain compounds in a manner similar to humans, making them highly relevant in preclinical safety studies. It is important to note that the dogs in this GLP study were dosed at much higher levels than the intended human dose which further reinforces the safety profile of NYR-BI03.

NYR-BI03 is a first-in-class neuroprotection treatment being developed for both stroke and traumatic brain injury (TBI). In February 2024, the Company announced preclinical stroke study results showing NYR-BI03 achieved a statistically significant neuroprotective effect, rescuing 42% of brain tissue in the penumbra region of treated animals. GLP studies to evaluate the safety and tolerability of NYR-BI03 were initiated in late 1QCY2024 (quarter ending March 2024).

This is the sixth successful GLP study out of the nine required to move NYR-BI03 into the clinic. Canary Capital remains confident that Nyrada will be in a position to commence a first in-human Phase I clinical trial for NYR-BI03 in late CY2024.